Evidence map›Paper›PMID 38664843›Full record

ArticleAlzheimer's research & therapy2024

Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men.

Rongxiang Tang, Erik Buchholz, Anders M Dale, Robert A Rissman, Christine Fennema-Notestine, Nathan A Gillespie, Donald J Hagler, Michael J Lyons, Michael C Neale, Matthew S Panizzon and 5 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Rongxiang TangDepartment of Psychiatry, University of California San Diego, La Jolla, 92093, USA. rotang@health.ucsd.edu.
Erik BuchholzDepartment of Psychiatry, University of California San Diego, La Jolla, 92093, USA.
Anders M DaleDepartment of Radiology, University of California San Diego, La Jolla, 92093, USA.
Robert A RissmanDepartment of Neurosciences, University of California San Diego, La Jolla, 92093, USA.
Christine Fennema-NotestineDepartment of Psychiatry, University of California San Diego, La Jolla, 92093, USA.
Nathan A GillespieDepartment of Psychiatry, Virginia Institute for Psychiatric and Behavior Genetics, Virginia Commonwealth University, Richmond, VA, 23284, USA.
Donald J HaglerDepartment of Neurosciences, University of California San Diego, La Jolla, 92093, USA.
Michael J LyonsDepartment of Psychological and Brain Sciences, Boston University, Boston, 02215, USA.
Michael C NealeDepartment of Psychiatry, Virginia Institute for Psychiatric and Behavior Genetics, Virginia Commonwealth University, Richmond, VA, 23284, USA.
Matthew S PanizzonDepartment of Psychiatry, University of California San Diego, La Jolla, 92093, USA.
Olivia K PuckettDepartment of Psychiatry, University of California San Diego, La Jolla, 92093, USA.
Chandra A ReynoldsDepartment of Psychology and Neurosciences, University of Colorado Boulder, Boulder, 80309, USA.
Carol E FranzDepartment of Psychiatry, University of California San Diego, La Jolla, 92093, USA.
William S Kremen *Department of Psychiatry, University of California San Diego, La Jolla, 92093, USA.
Jeremy A Elman *Department of Psychiatry, University of California San Diego, La Jolla, 92093, USA.
University of California San Diego · USVirginia Commonwealth University · USBoston University · USUC San Diego Health System · USUniversity of Colorado Boulder · US

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
TRIAL OF VALPROATE TO ATTENUATE THE PROGRESSION OF ADU01AG010483 · NIA · UNIVERSITY OF ROCHESTER · PI AISEN, PAUL S. · 1991 to 2012
$116.2M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOUGLAS R GALASKO · 2019 to 2026
$34.9M
The VETSA Longitudinal Twin Study of Cognition and Aging (VETSA 4)R01AG050595 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ELMAN, JEREMY A, FRANZ, CAROL ELAINE · 2015 to 2024
$28.0M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI · 2020 to 2026
$27.8M
The VETSA Longitudinal MRI Twin Study of AgingR01AG022381 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KREMEN, WILLIAM S. · 2003 to 2019
$22.3M
Urban Air Pollution and Pathological Brain Aging: A Nationwide Twin Study in MenP01AG055367 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEN, JIU-CHIUAN · 2018 to 2022
$11.5M
The VETSA Longitudinal MRI Twin Study of Aging (VETSA MRI 4)R01AG076838 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ANDERS M DALE, Jeremy A Elman · 2022 to 2026
$8.7M
Genetic Predictors, Transcriptomic Biomarkers, & Neurobiological Signatures of Resilience to Alzheimer's DiseaseR01AG064955 · NIA · UPSTATE MEDICAL UNIVERSITY · PI FENNEMA-NOTESTINE, CHRISTINE, GLATT, STEPHEN J · 2019 to 2023
$3.8M
Proinflammatory Endophenotype to predict NSAID treatment response Alzheimer's trialsR01AG051848 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI LYKETSOS, CONSTANTINE G, O'BRYANT, SID E · 2016 to 2020
$3.7M
A Blood Test for Screening Into Alzheimer's Prevention TrialsR01AG058252 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E, RISSMAN, ROBERT · 2017 to 2021
$3.2M
Gene-Environment Interplay of Social Contexts and Aging-Related OutcomesR01AG037985 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PEDERSEN, NANCY L · 2010 to 2014
$3.2M
NIA NIH HHS K01 AG063805NIA NIH HHS P01 AG055367NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG066530NIA NIH HHS R01 AG022381NIA NIH HHS R01 AG037985NIA NIH HHS R01 AG050595NIA NIH HHS R01 AG051848NIA NIH HHS R01 AG058252NIA NIH HHS R01 AG064955NIA NIH HHS R01 AG076838NIA NIH HHS RF1 AG073979NIA NIH HHS U01 AG010483NIA NIH HHS U24 AG057437
6 · The paper itself

Abstract

backgroundPlasma neurofilament light chain (NfL) is a promising biomarker of neurodegeneration with potential clinical utility in monitoring the progression of neurodegenerative diseases. However, the cross-sectional associations of plasma NfL with measures of cognition and brain have been inconsistent in community-dwelling populations.

methodsWe examined these associations in a large community-dwelling sample of early old age men (N = 969, mean age = 67.57 years, range = 61-73 years), who are either cognitively unimpaired (CU) or with mild cognitive impairment (MCI). Specifically, we investigated five cognitive domains (executive function, episodic memory, verbal fluency, processing speed, visual-spatial ability), as well as neuroimaging measures of gray and white matter.

resultsAfter adjusting for age, health status, and young adult general cognitive ability, plasma NfL level was only significantly associated with processing speed and white matter hyperintensity (WMH) volume, but not with other cognitive or neuroimaging measures. The association with processing speed was driven by individuals with MCI, as it was not detected in CU individuals.

conclusionsThese results suggest that in early old age men without dementia, plasma NfL does not appear to be sensitive to cross-sectional individual differences in most domains of cognition or neuroimaging measures of gray and white matter. The revealed plasma NfL associations were limited to WMH for all participants and processing speed only within the MCI cohort. Importantly, considering cognitive status in community-based samples will better inform the interpretation of the relationships of plasma NfL with cognition and brain and may help resolve mixed findings in the literature.

Indexed as

BiomarkersCognitionCognitive DysfunctionIndependent LivingNeurofilament ProteinsNeuroimagingNeuropsychological TestsAgedAgingBrainCross-Sectional StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedWhite MatterBiomarkersneurofilament protein LNeurofilament ProteinsBlood-based biomarkersNeurodegenerationNeurofilament light chainProcessing speedWhite matter hyperintensity

Identifiers

PMID38664843
PMCPMC11044425
OpenAlexW4395463178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.